Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CD69 | Q07108 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16298958 | 0.83 | ALOX15 (0.39) | MEN1KMT2AALDH1A1LMNAKDM4E | |
| SCHEMBL10102507 | 0.78 | GABRA1 (0.40) | TSHRALDH1A1LMNAKDM4EMAPT | |
| SCHEMBL22131068 | 0.76 | MEN1 (0.60) | MEN1KMT2AALDH1A1LMNAKDM4E | |
| SCHEMBL22016055 | 0.76 | MEN1 (0.60) | MEN1KMT2AALDH1A1LMNAKDM4E | |
| SCHEMBL13930455 | 0.75 | LOXL2 (0.33) | TSHRALDH1A1LMNA | |
| SCHEMBL3224516 | 0.71 | CA12 (0.48) | TSHRMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL22131077 | 0.70 | MEN1 (0.53) | TSHRMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL1387848 | 0.70 | RXRA (0.38) | TSHRMEN1KMT2AALDH1A1CD69 | |
| SCHEMBL29042657 | 0.69 | ALDH1A1 (0.39) | MEN1KMT2AALDH1A1CD69MAPT | |
| SCHEMBL13930456 | 0.69 | ALDH1A1 (0.51) | MEN1KMT2AALDH1A1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119103-B2 | Bifunctional resorcinol, thioresorcinol, and dithioresorcinol derivative metal chelating conjugates | MALLINCKRODT LLC (US) | 2012-02-21 | — | — | US | disclosed |
| US-20090082324-A1 | Bifunctional Resorcinol, Thioresorcinol, and Dithioresorcinol Derivative Metal Chelating Conjugates | INFACARE PHARMACEUTICAL CORPORATION | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082324-A1 | Bifunctional Resorcinol, Thioresorcinol, and Dithioresorcinol Derivative Metal Chelating Conjugates | SPR, QDPR, SLC40A1 | TSHR 209/4885MEN1 1017/4885KMT2A 1441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.